The New York Times
1 个月前
RT @PamBelluck: The new Alzheimer’s drug should only be used for a much narrower group of patients than the F.D.A.’s label allows, experts said. Even a strong supporter of approval said “there’s no evidence that it could be beneficial for any other stage of Alzheimer’s.”



评论 0
中文(简体) 中文(繁體) English 한국어 日本語 العربية Polski Deutsch Русский язык Français suomi Tagalog Nederlands Čeština Bahasa Melayu Português Svenska ไทย Türkçe Español Italiano हिन्दी, हिंदी Bahasa Indonesia Tiếng Việt Kiswahili Burmese English(British) français(canadien) ខ្មែរ, ខេមរភាសា, ភាសាខ្មែរ Português(Brasil) Español(Latinoamérica)